Names, aliases and forms
Potential effects and evidence map
Human agmatine sulfate evidence is limited and not centered on healthy cognition. Published human work provides safety and dose context in non-nootropic settings, while many brain and performance claims rely on mechanisms, animal pharmacokinetics, or preclinical research. Current evidence supports targeted cautions more than a broad moderate-risk label.
Agmatine should not be presented as a reliable focus or attention supplement for healthy users.
Direct memory enhancement is not well supported in healthy-user human studies.
Mood-related claims remain preliminary and should not be a primary supplement claim.
Agmatine has mechanistic brain-pathway literature, but user-facing long-term brain benefit claims are not well supported.
Typical dosages and timing
Many products use 500-1000 mg/day. Human agmatine sulfate research has used gram-range dosing in non-nootropic contexts, so do not copy those protocols into general supplement use.
Onset, duration and tolerance
Human agmatine sulfate studies used repeated daily dosing over 10-21 days, 14 days, or 2 months in pain-related contexts. Those study courses should not be displayed as single-dose duration for cognition, pumps, or general nootropic use.
Some clinical papers cite an apparent human blood The time for blood levels to fall by half during the final elimination phase.Source around 2 hours after ingestion, but the source trail is indirect and does not establish a human nootropic effect duration.
A rat study found oral plasma half-life around 74-117 minutes and longer CNS tissue kinetics after intravenous dosing. That supports cautious PK context only; it should not be converted into a human duration claim.
Safety, side effects and risk profile
Agmatine has preclinical, dose- and route-dependent vascular effects, so people prone to low blood pressure or using blood-pressure, nitrate, or glucose-lowering regimens should be cautious.
GI discomfort, diarrhea, or nausea can occur, especially at higher gram-range intakes.
Headache, flushing, dizziness, or lightheadedness are plausible tolerance issues but are not a strong signal in the limited human studies.
The main buyer risk is evidence overreach: healthy-user nootropic claims are much weaker than mechanistic marketing suggests.
U.S. supplement claims should stay within dietary-supplement rules and avoid implying clinical care outcomes.
Human studies generally report good tolerability. The clearest dose-related issue is GI tolerance: mild-to-moderate diarrhea and mild nausea were reported in the highest-dose cohort of a dose-escalation study and resolved after treatment stopped.
Legal and regulatory status
In the U.S., agmatine products sold as supplements should avoid clinical-care claims and should not present mechanism-only evidence as established benefit.
FAQ
Is agmatine a nootropic?
Not in a strong evidence-based sense. It has interesting mechanisms, but direct healthy-user focus and memory evidence is limited.
How much agmatine is typical?
Many consumer products use 500-1000 mg/day. Higher gram-range protocols from non-nootropic research should not be treated as a general target.
How fast does agmatine work, and how long does it last?
7For nootropic use, there is no reliable human acute-onset or single-dose duration value. Human studies used repeated daily dosing in non-nootropic pain contexts, while apparent human clearance and animal PK data are only indirect context.
Why mention blood-pressure context?
4Agmatine intersects with nitric-oxide, imidazoline, and other vascular pathways, and a preclinical review found dose- and route-dependent cardiovascular effects. That supports a targeted caution, but limited human supplement studies do not support treating agmatine as broadly high-risk.
What claims should be treated cautiously?
Be cautious with memory, mood, pain, pump, neuroprotection, or duration claims unless the product cites human evidence for the exact outcome, form, and dose. Mechanisms and animal kinetics should not be treated as human effect duration.
References
- PubChem Compound Summary for Agmatine. National Center for Biotechnology Information.
- Keynan O, Mirovsky Y, Dekel S, Gilad VH, Gilad GM. Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. Pain Med. 2010;11(3):356-368.
- Evidence for safety of the dietary ingredient agmatine sulfate as assessed by mutagenicity and genotoxicity studies. Toxicol Rep. 2024;13:101720.
- Exploring the Cardiovascular Impacts of Agmatine: A Systematic Review. Med Sci (Basel). 2025;13(4):255.
- Piletz JE, Aricioglu F, Cheng JT, et al. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs. 2007;21(11):885-900.
- U.S. Food and Drug Administration. Dietary Supplements.
- Rosenberg ML, Tohidi V, Sherwood K, et al. Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. Nutrients. 2020;12(2):576.
- Gilad GM, Gilad VH. Long-term (5 years), high daily dosage of dietary agmatine--evidence of safety: a case report. J Med Food. 2014;17(11):1256-1259.
- Clements BM, Peterson CD, Kitto KF, Caye LD, Wilcox GL, Fairbanks CA. Biodistribution of Agmatine to Brain and Spinal Cord after Systemic Delivery. J Pharmacol Exp Ther. 2023;387(3):328-336.